The Molecular Pathway of p75 Neurotrophin Receptor (p75NTR) in Parkinson’s Disease: The Way of New Inroads

Ali, Naif H.; Al-kuraishy, Hayder M.; Al-Gareeb, Ali I.; Alnaaim, Saud A.; Saad, Hebatallah M.; Batiha, Gaber El-Saber

doi:10.1007/s12035-023-03727-8

Cited by 11 publications

(2 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 13 In PD, non‐motor symptoms such as dementia, cognitive dysfunction, sleep disorders and depression may emerge several decades before the advancement of motor symptoms. 14 , 15 Among people over 60, PD affects 1%–3% of the population. 16 The primary risk factor for PD and a strong predictor of the disease's severity is ageing.…”

Section: Pathogenesis and Clinical Feature Of Pdmentioning

confidence: 99%

“…PD is distinguished by motor manifestations such as tremors, rigidity, postural instability and bradykinesia 13 . In PD, non‐motor symptoms such as dementia, cognitive dysfunction, sleep disorders and depression may emerge several decades before the advancement of motor symptoms 14,15 . Among people over 60, PD affects 1%–3% of the population 16 .…”

Section: Pathogenesis and Clinical Feature Of Pdmentioning

confidence: 99%

See 1 more Smart Citation

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Ali,

Al‐Kuraishy,

Al‐Gareeb

et al. 2024

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Parkinson's disease (PD) is a neurodegenerative disorder of the brain and is manifested by motor and non‐motor symptoms because of degenerative changes in dopaminergic neurons of the substantia nigra. PD neuropathology is associated with mitochondrial dysfunction, oxidative damage and apoptosis. Thus, the modulation of mitochondrial dysfunction, oxidative damage and apoptosis by growth factors could be a novel boulevard in the management of PD. Brain‐derived neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase type B (TrkB) are chiefly involved in PD neuropathology. BDNF promotes the survival of dopaminergic neurons in the substantia nigra and enhances the functional activity of striatal neurons. Deficiency of the TrkB receptor triggers degeneration of dopaminergic neurons and accumulation of α‐Syn in the substantia nigra. As well, BDNF/TrkB signalling is reduced in the early phase of PD neuropathology. Targeting of BDNF/TrkB signalling by specific activators may attenuate PD neuropathology. Thus, this review aimed to discuss the potential role of BDNF/TrkB activators against PD. In conclusion, BDNF/TrkB signalling is decreased in PD and linked with disease severity and long‐term complications. Activation of BDNF/TrkB by specific activators may attenuate PD neuropathology.

show abstract

Section: Pathogenesis and Clinical Feature Of Pdmentioning

confidence: 99%

Section: Pathogenesis and Clinical Feature Of Pdmentioning

confidence: 99%

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Ali,

Al‐Kuraishy,

Al‐Gareeb

et al. 2024

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

show abstract

Role of uric acid in neurodegenerative diseases, focusing on Alzheimer and Parkinson disease: A new perspective

Alrouji,

Al‐kuraishy,

Al‐Gareeb

et al. 2024

Neuropsychopharm Rep

View full text Add to dashboard Cite

Neurodegenerative diseases (NDs) such as Alzheimer disease (AD) and Parkinson disease (PD) are group of diseases affecting the central nervous system (CNS) characterized by progressive neurodegenerations and cognitive impairment. Findings from different studies highlighted the beneficial and detrimental effects of serum uric acid on the development and progression of NDs. Therefore, this mini‐review aims to discuss the beneficial and detrimental effects of uric on NDs. The neuroprotective effect of uric acid is mainly related to the antioxidant effect of uric acid which alleviates oxidative stress‐induced neurodegeneration in AD and PD. However, long‐term effect of hyperuricemia prompts for the development and progression of cognitive impairment. Hyperuricemia is associated with cognitive impairment and dementia, and gout increases dementia risk. In addition, hyperuricemia can cause cerebral vascular injury which is a risk factor for vascular dementia and cognitive impairment. Taken together, the relationship between uric acid and NDs risk remains conflicting. Hence, preclinical and clinical studies are indicated in this regard.

show abstract